assembly
biosciences
ceo
john
mchutchison
named
recipient
prestigious
advance
global
impact
award
south
san
francisco
globe
newswire
assembly
biosciences
nasdaq
asmb
biotechnology
company
developing
innovative
therapeutics
targeting
hepatitis
b
virus
hbv
diseases
associated
microbiome
today
announced
john
mchutchison
ao
md
company
ceo
named
recipient
advance
global
impact
award
advance
awards
recognize
work
remarkable
global
australians
making
extraordinary
impact
worldwide
award
honors
mchutchison
innovative
work
developing
curative
therapies
patients
hepatitis
c
virus
hcv
treatments
part
result
personal
investment
researching
developing
therapeutics
previously
incurable
disease
helm
assembly
biosciences
mchutchison
dedicated
pioneering
new
class
therapeutics
hbv
impacts
approximately
million
people
globally
great
honor
named
winner
highly
prestigious
award
said
mchutchison
quarter
billion
people
worldwide
chronically
infected
hbv
deserve
better
outcomes
delivered
people
hcv
infection
contributions
hcv
field
recognized
advance
awards
commission
truly
inspiring
reinforces
commitment
confidence
achieve
future
curative
treatment
regimens
patients
hbv
ninth
year
advance
awards
celebrates
australian
global
leaders
represent
extraordinary
group
talented
innovators
demonstrated
excellence
respective
fields
global
stage
ranging
technology
innovation
financial
services
healthcare
social
impact
sustainability
arts
awards
kind
recognize
contributions
one
million
australians
living
abroad
full
list
advance
award
recipients
available
information
assembly
biosciences
available
assembly
biosciences
assembly
biosciences
biotechnology
company
developing
innovative
therapeutics
targeting
hepatitis
b
virus
hbv
diseases
associated
microbiome
hbv
program
focused
advancing
new
class
potent
oral
core
inhibitors
potential
increase
cure
rates
chronically
infected
patients
microbiome
program
developing
novel
oral
live
microbial
biotherapeutic
candidates
assembly
fully
integrated
platform
including
robust
process
strain
identification
selection
gmp
manufacturing
expertise
targeted
delivery
lower
gastrointestinal
tract
technology
information
visit
investor
contact
assembly
biosciences
lauren
glaser
senior
vice
president
investor
relations
corporate
affairs
media
contact
sam
brown
audra
friis
